Harnessing the immune system with epigenetic therapies to treat HER2+ breast cancer
This project explores the anti-cancer activity and mechanisms of action of novel drug combinations for the treatment of HER2+ breast cancer. Findings from this study will directly aid the clinical development and implementation of these promising anti-HER2-based combination therapies.
Dr Nicole Haynes, Prof Ricky Johnstone, A/Prof Sherene Loi
Cancer Council Research Grant
Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology
$99,771 in 2016, $99,840 in 2017 and $99,635 in 2018